Agios Pharmaceuticals clinical trials we track

Check company identity source

Phase 3 8 trials

TrialDrugs studiedStatusPrimary completion
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)NCT07656415MitapivatRecruiting2029-08Estimated
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)NCT07506863MitapivatRecruiting2029-06Estimated
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent ThalassemiaNCT07517133MitapivatRecruiting2029-03Estimated
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension PeriodNCT05175105MitapivatActive not recruiting2024-12-13Actual
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension PeriodNCT05144256MitapivatActive not recruiting2024-05-03Actual
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)NCT04770779MitapivatActive not recruiting2024-04-11Actual
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)NCT04770753MitapivatActive not recruiting2023-11-13Actual
Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007NCT03853798MitapivatCompleted2024-07-03Actual

Phase 2 / 3 2 trials

Phase 2 4 trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2027-02-01DayMitapivatAgios Pharmaceuticals, Inc. · AGIOCompany-disclosed PDUFA goal dateAnnounced review targetsickle cell diseaseOpen original source
Read source excerpt

We submitted a supplemental New Drug Application, or sNDA, for the U.S. accelerated approval of mitapivat in sickle cell disease, or SCD, in May 2026, which was accepted with priority review by the FDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of November 1, 2026. The PDUFA goal date was subsequently extended to February 1, 2027 following our response to an FDA information request to inform its evaluation as to whether a REMS is necessary for mitapivat in SCD.

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026

2027-02-01DayMitapivatAgios Pharmaceuticals, Inc. · AGIOCompany-disclosed PDUFA goal dateAnnounced review targetSCDOpen original source
Read source excerpt

We submitted an sNDA for the U.S. accelerated approval of mitapivat in SCD in May 2026, which was accepted with priority review by the FDA and granted a PDUFA goal date of November 1, 2026. The PDUFA goal date was subsequently extended to February 1, 2027 following our response to an FDA information request to inform its evaluation as to whether a REMS is necessary for mitapivat in SCD.

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026

2027-02-01DayMitapivatAgios Pharmaceuticals, Inc. · AGIOCompany-disclosed PDUFA goal dateAnnounced review targetsickle cell diseaseOpen original source
Read source excerpt

New PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 56 participants (planned). After: 59 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 4 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 82 participants (planned). After: 87 participants (actual).

Primary completion date changed

Before: Nov 2025. After: Mar 2026.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source